In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novimmune SA

Latest From Novimmune SA

Novimmune Sells Gamifant And IO Assets To Sobi

Swiss biotech Novimmune SA creates newco around Gamifant emapalumab and other immuno-oncology assets and then sells it to Sobi for CHF515m ($519.2m).
Commercial ImmunoOncology

Sobi Realigns Focus On Late-Stage Hematology & Immunology Assets

Swedish specialty pharma and rare diseases company seeks to sustain recent rapid revenues growth with increased R&D focus and investments in its hematology and immunology franchises.

BioPharmaceutical Immune Disorders

Keeping Track: US FDA Enters Year's Final Stretch With Tsunami Of Novel Approvals

The latest drug development news and highlights from our US FDA Performance Tracker.
Drug Review Regulation

Sobi Advances Growth Strategy With Gamifant Launch In Early 2019 For Primary HLH

The interferon gamma blocker is the first new therapy for HLH in 24 years. FDA approval came about four months after Sobi acquired global rights from NovImmune in a deal meant to improve the company's growth prospects.

Approvals Rare Diseases
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Inflammation
  • Alias(es)
  • NovImmune SA
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Novimmune SA
  • Senior Management
  • Erik Trock-Jansen, CEO
    Sven Zimmermann, CFO
    Adrian Mills, CBO
    Cristina de Min , MD, CMO
  • Contact Info
  • Novimmune SA
    Phone: (41) 22 839 71 41
    14 Chemin des Aulx
    Geneva, 1228